NCT01902472

A Prospective, Observational Study of Individuals Who Seroconvert While Taking Truvada® for Pre-Exposure Prophylaxis (PrEP)

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 172 (actual)
• Sponsor: Gilead Sciences · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate HIV-1 RNA and the presence or absence of resistance at baseline and following seroconversion, assess the frequency of HIV-1 screening and screening method(s) used for evaluation of seroconverters, and collect information regarding whether the seroconverter experienced signs and symptoms of acute HIV-1 infection prior to or at the time of seroconversion.

Conditions

• HIV

Timeline

• Start date: 2013-09-02
• Primary completion: 2017-10-30
• Completion: 2017-10-30
• First posted: 2013-07-18
• Last updated: 2020-07-14

Locations

1 site across 1 country: United States